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Abbreviations
!
CI confidence interval
C-RADS CT Colonography Reporting and Data
System
CRC colorectal cancer
CT computed tomography
CTC computed tomographic colonography
ESGAR European Society of Gastrointestinal and
Abdominal Radiology
ESGE European Society of Gastrointestinal
Endoscopy
FIT fecal immunochemical test
FOBT fecal occult blood testing
GRADE Grading of Recommendations Assess-
ment, Development and Evaluation
NPV negative predictive value
PEG polyethylene glycol
PPV positive predictive value
RCT randomized controlled trial
SIGGAR Special Interest Group in Gastrointesti-
nal and Abdominal Radiology
This is an official guideline of the European Society of
Gastrointestinal Endoscopy (ESGE) and the European So-
ciety of Gastrointestinal and Abdominal Radiology (ES-
GAR), published in Endoscopy and European Radiology si-
multaneously. It addresses the clinical indications for the
use of computed tomographic colonography (CTC). A tar-
geted literature search was performed to evaluate the
evidence supporting the use of CTC. The Grading of Re-
commendations Assessment, Development and Evaluati-
on (GRADE) system was adopted to define the strength
of recommendations and the quality of evidence.
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Main recommendations
1 ESGE/ESGAR recommend computed tomo-
graphic colonography (CTC) as the radiological
examination of choice for the diagnosis of colo-
rectal neoplasia. ESGE/ESGAR do not recom-
mend barium enema in this setting (strong re-
commendation, high quality evidence).
2 ESGE/ESGAR recommend CTC, preferably the
same or next day, if colonoscopy is incomplete.
Delay of CTC should be considered following
endoscopic resection. In the case of obstructing
colorectal cancer, preoperative contrast-en-
hanced CTC may also allow location or staging
of malignant lesions (strong recommendation,
moderate quality evidence).
3 When endoscopy is contraindicated or not
possible, ESGE/ESGAR recommend CTC as an
acceptable and equally sensitive alternative for
patients with symptoms suggestive of colorectal
cancer (strong recommendation, high quality
evidence).
4 ESGE/ESGAR recommend referral for endo-
scopic polypectomy in patients with at least
one polyp≥6mm in diameter detected at CTC.
CTC surveillance may be clinically considered if
patients do not undergo polypectomy (strong
recommendation, moderate quality evidence).
5 ESGE/ESGAR do not recommend CTC as a pri-
mary test for population screening or in individ-
uals with a positive first-degree family history of
colorectal cancer (CRC). However, it may be pro-
posed as a CRC screening test on an individual
basis providing the screenee is adequately in-
formed about test characteristics, benefits, and
risks (weak recommendation, moderate quality
evidence).
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Introduction
!
Colorectal cancer (CRC) is a major cause of morbidity andmortal-
ity [1,2]. CRC screening by fecal occult blood testing (FOBT) has
been shown to reduce CRC mortality [3,4], and is currently used
in several European countries. Colonoscopy is highly effective for
detecting advanced neoplasia, and endoscopic polypectomy re-
duces subsequent CRC-specific incidence and mortality [5]. In
Europe, colonoscopy is mainly used to investigate FOBT-positive
or symptomatic patients, or as a preventive strategy in thosewith
increased CRC risk [6].
Computed tomographic colonography (CTC) is a minimally inva-
sive imaging technique that is highly accurate for detecting colo-
rectal cancer (CRC) and adenomatous polyps. The technique is
standardized [7], and CTC is more easily performed than barium
enema. Evidence-based data suggest that CTC is the natural re-
placement for barium enema and a complementary rather than
an alternative examination to colonoscopy. However, the clinical
scenarios for which CTC is indicated remain unclear. To address
this uncertainty–20 years after the first presentation of CTC at a
radiological meeting [8]– the European Society of Gastrointesti-
nal Endoscopy (ESGE) and the European Society of Gastrointesti-
nal and Abdominal Radiology (ESGAR) decided to produce a com-
mon guideline regarding indications for CTC in clinical practice.
Technical and quality issues of CTC have been deliberately ex-
cluded from this work as these have already been discussed sep-
arately [7].
Methods
!
The ESGE and ESGAR commissioned this Guideline (chairs C.S.
and A.L.) and invited the listed authors to participate in the devel-
opment of the Guideline. The key questions were prepared by the
coordinating team (C.S.and A.L.) and then approved by the other
members (see Appendix e1, available online). The coordinating
team convened subgroup task forces, each with one radiologist
and one endoscopist lead, and allocated the key questions to
these task forces.
Each task force performed a systematic literature search to pre-
pare evidence-based statements on their assigned key questions.
Medline, EMBASE and other databases were searched including
the following search terms as minimum: colon, cancer or malig-
nancy or neoplasm, and CTC. All articles investigating CTC in
symptomatic or screening contexts were selected by inspecting
the title and abstract. Hereditary colorectal syndromes were ex-
cluded. After further exploration of the content, each task force
summarized the included articles in a table of evidence (see Ap-
pendix e2, available online). All selected articles were graded on
level of evidence and strength of recommendation according to
the GRADE system [9, 10]. The literature searches were updated
to September 2013.
Each task force prepared statements answering their assigned
key questions. The statements were discussed subsequently and
voted on during a face-to-face meeting of the whole group held
on 1 October 2013. In May 2014, a draft prepared by the coordi-
nating team was sent to all group members for comment. After
agreement on a final version, the manuscript was reviewed by
two experts selected by the ESGE and ESGAR Governing Boards
and then submitted to the journals of ESGE and ESGAR.
This Guidelinewill be reviewed in 2019, or sooner if relevant new
evidence becomes available. Any updates to the Guideline in the
interim will be noted on the websites of ESGE (http://www.esge.
com/esge-guidelines.html) and ESGAR (http://www.esgar.org).
Recommendations and statements
!
Evidence statements and recommendations are stated in italics,
key evidence statements and recommendations are in bold.
CT colonography (CTC) and diagnosis of
colorectal neoplasia
!
ESGE/ESGAR recommend computed tomographic colonography
(CTC) as the radiological examination of choice for the diagnosis of
colorectal neoplasia. ESGE/ESGAR do not recommend barium enema
in this setting (strong recommendation, high quality evidence).
Computed tomographic colonography (CTC) can be considered to
be the best radiological test for the diagnosis of colorectal cancer.
Several randomized [11–13], multicenter [14,15], and single-
center trials [16–18], and meta-analyses [19–26], have shown
that regarding accuracy for both colorectal cancer (CRC) and
large/advanced polyps, CTC is similar to colonoscopy in sympto-
matic and asymptomatic patients and is clearly superior to bar-
ium enema [11]. In a recent randomized trial (the SIGGAR trial)
[11,13] comparing CTC with colonoscopy and barium enema,
the detection rate for colorectal cancer or large polyps was signif-
icantly higher in patients assigned to CTC than in those assigned
to barium enema (7.3% vs 5.6%, P<0.039) but similar for colonos-
copy and CTC (11% for both procedures).
In a comparative study between colonoscopy and barium enema
[27], the sensitivity and specificity of barium enemawere respec-
tively 38% and 86% for polyps of any size. In another publication
[28], using a 5-mm threshold, per-patient sensitivity and specifi-
city of barium enema were respectively 41% and 82%; at a
threshold greater than 10mm, these values were respectively
48% and 90%.
In a meta-analysis comparing the performance of barium enema
with CTC [29] for detection of colorectal polyps ≥6mm in average
risk and high risk patients, CTC was more specific and more sen-
sitive than barium enema for large polyps (≥10mm) and small
polyps (6–9mm), in both per-patient and per-polyp analysis. In
the per-patient analysis, CTC showed an incremental diagnostic
yield in sensitivity of 12.0% for polyps ≥10mm and of 30.1% for
polyps of 6–9mm, and in specificity of 10.3% for polyps ≥10mm.
Apart from better diagnostic performance, CTC is more tolerable
and acceptable to patients and delivers a lower effective radiation
dose than barium enema [30].
CT colonography following incomplete colonoscopy
!
ESGE/ESGAR recommend CT colonography (CTC), preferably the
same or next day, if colonoscopy is incomplete. Delay of CTC should
be considered following endoscopic resection. In the case of obstruct-
ing colorectal cancer, preoperative contrast-enhanced CT colonogra-
phy may also allow location or staging of malignant lesions. (strong
recommendation, moderate quality evidence).
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Incomplete colonoscopy has been reported to occur in 10%–15%
of all colonoscopies [31,32], and it has been associated with a
higher risk of interval cancers in epidemiological studies [33]. In-
complete colonoscopy may be addressed by repetition of colo-
noscopy or by radiological procedures. Repeat colonoscopy is
likely to be considered when the reason for the previous failure
was inadequate bowel preparation [34,35]. On the other hand,
radiological referral appears most frequently indicated in the
case of difficult anatomy or patient intolerance [35]. Several stud-
ies [36–46] have investigated CTC as a completion procedure fol-
lowing incomplete colonoscopy. These studies show high techni-
cal feasibility, a relatively high diagnostic yield, and an adequate
positive predictive value (PPV), especially at a 10-mm threshold.
However, none of the studies employed an independent refer-
ence standard for individuals with negative CTC findings, so that
the accuracy of CTC in this setting is unknown. However, there is
no apparent reason why the high accuracy shown by CTC in both
asymptomatic and symptomatic settings, especially for large
polyps or CRC, should not be extrapolated to those individuals
with incomplete colonoscopy. For this reason, the superiority of
CTC over barium enema recently shown in a large randomized
study [11] should favor performance of CTC rather than barium
enema following an incomplete colonoscopy.
Timing of CTC after incomplete colonoscopy
CTC after incomplete colonoscopy requires a different approach
from primary CTC. When endoscopic biopsy has been done, CTC
can be performed on the same day as the endoscopic procedure.
An ultralow/low dose pre-CTC scan of the abdomen and pelvis
before insertion of the rectal tube may rule out the presence of
extraluminal gas that would indicate a colonoscopic perforation.
In detail, in 262 patients undergoing CTC after incomplete colo-
noscopy, 2 perforations were detected (0.8%, 95% confidence in-
terval [95%CI] 0.1–2.7) [47]. In the case of endoscopic resection
(i.e. polypectomy/mucosectomy), it is prudent to consider an ap-
proximately 2-week delay before performing CTC. However,
there is little scientific evidence concerning the interval be-
tween endoscopic resection and subsequent CTC, thus for each
case there should be a clinical discussion between the endos-
copist and the radiologist. However, in a recent study on 65
CRC patients with severe luminal narrowing after incomplete
colonoscopy with either polypectomy or biopsy sampling, no ex-
traluminal gas was detected at CTC within 24 hours [48]. Other
evidence for the safety of radiologic imaging after endoscopic
biopsy comes from barium enema studies, both experimental
and clinical [49–52]. These studies concluded that in a nondi-
seased colon, barium enema could be performed immediately
after endoscopic biopsy without any risk. In the case of endo-
scopic resection, barium enema could be performed without
any risk after 6 days.
Incomplete colonoscopy due to obstructing CRC
Accurate preoperative assessment of the whole colon is required
to exclude synchronous CRC. In a recent population-based study
of 13 683 Dutch patients diagnosed with CRC, 3.9% were diag-
nosed with synchronous CRC, and in 34% of these cases the two
tumors were located in different surgical segments [53]. These
data were in line with those from a previous French study [54]
and from other series [55]. Failure to detect synchronous cancer
can increase morbidity, and one study has shown that intraoper-
ative palpation can miss up to 69% of synchronous malignancies
[56,57]. Thus, preoperative whole-colon assessment is needed.
CTC appears to be an effective and safe choice when obstructing
CRC prevents a complete endoscopic assessment or when cecal
intubation fails for other reasons. A recent study including 286
CRC cases after failed colonoscopy showed CTC negative predic-
tive values (NPVs) of 100% and 97% for synchronous cancer and
advanced neoplasia, respectively, in a preoperative setting [58].
This is in line with a previous systematic review, showing equiva-
lent sensitivity of colonoscopy and CTC for established cancer
[22], and in line with findings from similar cohort studies [44,
59–63].
Patients with abdominal symptoms suggestive of
colorectal cancer
!
When endoscopy is contraindicated or not possible, ESGE/ESGAR re-
commend CT colonography (CTC) as an acceptable and equally sensi-
tive alternative for patients with symptoms suggestive of colorectal
cancer (strong recommendation, high quality evidence).
Patients with abdominal symptoms suggestive of colorectal can-
cer (CRC) require detailed investigation, since neither clinical ex-
amination nor fecal testing reliably excludes CRC [64]. The ideal
test would also diagnose non-neoplastic conditions responsible
for the symptoms (both within the colon and beyond it). Patient
acceptability and safety are also important.
Colorectal neoplasia
In the SIGGAR trial no significant difference in the detection rates
for large polyps (≥10mm) and for colorectal cancer was demon-
strated between CTC and colonoscopy [13]. Furthermore, the
crude pooled sensitivity of CTC for colorectal cancer in the stud-
ies of symptomatic patients was 96% (169 out of 176 colorectal
cancers detected) [13]. This is compatible with the 96.1% sensi-
tivity of CTC for colorectal cancer that was reported in a meta-a-
nalysis [22] that included both screening and symptomatic/high
risk patients. When large polyps (≥10mm) only were consid-
ered, per-patient sensitivity of CTC ranged from 82% to 92% in
six meta-analyses that included screening, symptomatic, high
risk, and FOBT-positive patients [19–21, 23,25,26]. In the studies
specifically investigating symptomatic patients, pooled sensitiv-
ity for large≥10-mm lesions (excluding cancers) was 91.4% (53
of 58 patients).
These data suggest that CTC and colonoscopy have similar sensi-
tivity for detecting CRC and large polyps in symptomatic patients.
Small polyps (6–9mm) and diminutive polyps (≤5mm) are less
relevant in symptomatic patients, since they cannot explain the
patient’s symptoms. Nonetheless, the ability to opportunistically
detect and remove early precursor lesions and perform histopa-
thologic analysis of diagnosed CRC remains a potential advantage
of colonoscopy over CTC.
Colorectal non-neoplastic disease
Abdominal symptoms may be due to non-neoplastic colonic con-
ditions, for which both CTC and colonoscopy may be useful. Di-
verticulosis is more commonly demonstrated at CTC than colo-
noscopy [13,65], although the relationship between diverticulo-
sis and symptoms is less clear. Colonoscopy is more sensitive for
the detection of colitis and anal pathology [13]; furthermore it
offers the possibility of sampling tissue.
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Extracolonic findings
CTC is an abdominal CT examinationwith the ability to detect ex-
tracolonic diseases. Although these extracolonic lesions may oc-
casionally explain the symptoms, on the other hand, incidental
findings that ultimately prove unimportant may prompt addi-
tional tests that are inconvenient, costly, and even harmful. Few
studies of extracolonic findings focus specifically on symptomatic
patients, in whom there is a higher prevalence of significant ab-
normality. The two largest series, of screening [66] and sympto-
matic [11,13] patients, respectively reported 0.35% and 1.9%
rates of extracolonic malignancy. Importantly, in the paired SIG-
GAR trials, at 3-year follow-up there was no significant difference
in rates of extracolonic malignancy between the two arms of each
of the trials (CTC vs. barium enema, and CTC vs. colonoscopy), al-
though all arms showed rates significantly above rates expected
for the general population. The latter observation may be ex-
plained by subsequent use of CT to investigate persistent symp-
toms in patients randomized to colonoscopy or barium enema,
although this remains unproven.
CT colonography and screening for colorectal cancer
!
ESGE/ESGAR do not recommend CT colonography (CTC) as a primary
test for population screening or in individuals with a positive first-de-
gree family history of colorectal cancer (CRC). However, it may be
proposed as a CRC screening test on an individual basis providing
the screenee is adequately informed about test characteristics, bene-
fits, and risks (weak recommendation, moderate quality evidence).
Accuracy of computed tomography colonoscopy (CTC)
To date, only guaiac FOBT (g-FOBT) and sigmoidoscopy have been
shown to reduce CRC mortality, by 16% and 22%–31% respec-
tively [67–69]. CTC has not been subjected to randomized trials
with CRC incidence or mortality as end points. Therefore, the ac-
curacy of CTC is used as a surrogate end point for CTC efficacy in a
screening setting.
CTC accuracy in average risk screening populations has been in-
vestigated by a recent meta-analysis [24], which estimated per-
patient sensitivity at 88% for advanced neoplasia ≥10mm. One
further primary study published after this review, showed sim-
ilar results [16]. In six screening studies, none of the 12 CRCs
present were missed by CTC in average risk individuals [14,16–
18,70–72]. Individuals with a positive family history of CRC or
adenomas should be considered to be at high risk [73]. One re-
cent cohort study showed a 89% sensitivity of CTC for advanced
neoplasia≥10mm in this setting [74].
CTC in screening: participation and yield
The efficacy of a screening program not only depends on the di-
agnostic accuracy of the screening test that is used, but also on
participation. This is illustrated by the results of a large popu-
lation-based randomized screening trial performed in the Neth-
erlands: participation rates for colonoscopy and CTC of 22% and
34%, respectively, were reported, and detection rates for ad-
vanced neoplasia of 8.7 and 6.1 persons per 100 participants,
respectively [12]. Despite the higher sensitivity of colonoscopy
and the fact that CTC participants were only referred to colonos-
copy if they had lesions≥10mm detected by CTC, the number of
individuals per 100 invitees found to have advanced neoplasia
was similar for both screeningmodalities, namely 1.9 (colonosco-
py) versus 2.1 (CTC) per 100 invitees [12]. The poorer sensitivity
of CTC comparedwith colonoscopy was countered by its approxi-
mately 1.5 times higher participation rate.
In the case of serrated adenomas the diagnostic yield of colonos-
copy was 5 times higher than that of CTC. This is of particular im-
portance, since approximately 10%–20% of CRC develops from
the serrated pathway [75].
The diagnostic yield of CTC screening per 100 invitees would ap-
pear to be significantly higher than the yield of first-round g-
FOBT, but similar to the yield of first-round flexible sigmoidosco-
py screening (2.2 per 100 invitees) and fecal immunochemical
testing (FIT) screening (2.0 per 100 invitees when using a cutoff
of 50 ngHb/mL) [76]. One should however bear in mind that
FOBT/FIT screening is repeated at 2-year intervals, whereas 5–
10-year intervals are usually recommended for CTC and endo-
scopic screening.
Acceptability of CTC screening
A recent meta-analysis included articles on preferences and dif-
ferences in burden for both average risk and high risk individuals
who had undergone CTC as well as colonoscopy (tandem design)
[77]. Amongst the included studies, 3573 patients reported a pre-
ference for CTC, 927 showed a preference for colonoscopy, and
1116 showed no difference in preference.
In a Dutch population-based screening trial, almost half of the
nonparticipants made an informed decision on participation as
they were provided with adequate knowledge of CRC and CRC
screening, and showed a positive attitude towards screening,
but nevertheless declined participation, which suggested that
additional barriers to participation were present [78]. The rea-
sons cited for declining screening by colonoscopy or by CTC
were similar overall [79]. However, colonoscopy invitees who de-
clined most often mentioned ‘unpleasantness of the examina-
tion’ as their prime reason, while for CTC invitees ‘no time/too
much effort’ and ‘lack of symptoms’ were most often cited. The
last finding is consistent with the findings of the study of Ho et
al., in which 38% did not participate in CTC screening because of
procrastination and 12% because they were too busy [80].
As indicated above, most previous screening studies, using a tan-
dem design to compare perceived acceptability and burden of the
two techniques, showed a significant preference for CTC, with 46
% to 95% of participants preferring CTC for future investigation
[17,81,82].
A recent Netherlands study performed within the population-
based screening trial mentioned above showed that colonoscopy
invitees expected the screening procedure and bowel prepara-
tion to be more burdensome than did CTC invitees [83]. CTC par-
ticipants in the Dutch study however found their screening pro-
cedure slightly more burdensome than did colonoscopy partici-
pants. Colonoscopy participants gave higher burden scores to in-
gesting the bowel preparation, while CTC participants gave high-
er burden scores to related bowel movements (i. e. diarrhoea and
bowel cramps). Although these differences were statistically sig-
nificant, they were mostly small and thus the clinical relevance is
limited for a clinical population, but more significant for a pri-
mary screening population. This is illustrated by the fact that in-
tended participation in a subsequent screening round exceeded
90% for both colonoscopy and CTC.
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Safety of CTC screening
Adverse events
The risk of major adverse events due to the CTC examination it-
self (including the bowel preparation) is low and presumed lower
than for colonoscopy [13,84]. Adverse events of CTC screening,
however, should include events related to the entire episode,
also including those related to any colonoscopy required to inves-
tigate CTC findings (e.g. post-polypectomy bleeding).
In a randomized trial comparing CTC with colonoscopy screen-
ing, serious adverse events were comparable for both procedures,
(0.2% for CTC; 0.3% for colonoscopy) [12]. These rates are similar
to adverse events observed in randomized trials of FOBT and of
flexible sigmoidoscopy screening [85]. In a recent meta-analysis
[86] on 103 399 asymptomatic and symptomatic patients, the
CTC perforation rate was estimated to be 0.04% overall; the rate
was 19-fold higher in symptomatic compared with screening in-
dividuals. The CTC-induced surgery rate was 0.008% and no CTC-
related deaths were reported.
Radiation risk in screening
Radiation exposure at CTC is associated with a risk of cancer in-
duction. This risk is relevant for all individuals but especially so
in screening where benefit should clearly outweigh potential
harm. The risk associated with ionizing radiation at a single CTC
is very small and has been estimated as an absolute lifetime can-
cer risk of 0.14% for a 50-year-old and 0.07% for a 70-year-old,
and can be reduced substantially with protocol optimization
[87]. Another study reported a less than 0.2% increase of the life-
time cancer risk in individuals undergoing CTC screening every 5
years between the ages of 50 and 80 years [88].
A study compared the anticipated cancer induced versus antici-
pated cancer prevented by CTC screening using the effective
dose of a screening study (7 mSv for men and 8 mSv for women)
[89]. In that study the radiation-related lifetime cancer risk for a
single screening CTC was 0.06% for a 50-year-old person and de-
creased with age. The corresponding calculated benefit–risk ra-
tio for a 50-year-old person ranged from 24:1 to 35:1 depending
on the model used. A recent international survey reported that
the effective dose of present day screening CTC was 4.4 mSv
[90], which is lower than used in the aforementioned study. Fur-
ther dose reduction is possible with technical developments such
as iterative reconstruction algorithms and lower tube voltage,
leading to doses of 1 mSv [91].
Extracolonic findings
Extracolonic findings are common at screening CTC and have
been reported to occur in from one quarter to more than one
half of screenees [92–97]. The incidence of extracolonic findings
increases significantly with age; one study reported extracolonic
findings in 55.4% of screenees younger than 65 years and in 74%
of those 65 years or older [96]. The large majority of extracolonic
findings are irrelevant and can be classified as such at CTC.
Work-up for (potentially) important extracolonic findings occurs
in approximately 10% of cases [97–99]. The prevalence of extra-
colonic findings of moderate or high importance at CTC is com-
monly reported to be approximately 10%–15% of screenees
[94, 95,98,99], although higher prevalence is occasionally report-
ed [92,100]. This difference is partly caused by variation in the
definition of moderate and high importance findings. The pro-
portion of findings of high importance is mostly in the order of
2%–5% [95,97,99], and includes approximately 0.5% extracolo-
nic cancers, of which renal cell cancer, lung cancer and lympho-
ma are most prevalent [66,97,99,100], and are usually localized
at the time of diagnosis [66]. Further important extracolonic
findings include abdominal aortic aneurysms, adrenal masses,
and nonmalignant renal masses.
The costs reported for the additional work-up of extracolonic
findings vary substantially and are influenced by the definition
of a relevant finding needing work-up and by which costs are in-
cluded. It appears that the average additional cost for extracolo-
nic findings at CTC is of the order of 20–50 USD averaged over all
attendees [94–96,100,101]. No studies report costs that might
be saved by earlier detection of disease.
CTC as a primary screening modality for CRC:
conclusions
Primary CTC and colonoscopy screening have similar yields for
advanced neoplasia per invitee. However, the impact of extraco-
lonic findings, both medically and economically, remains un-
known. Although radiation exposure is a drawback, this disad-
vantage seems to be overemphasised especially given the current
reduction in radiation exposure with CTC. Probably the most im-
portant factor is the question of whether CTC screening is cost-ef-
fective, and this is still unanswered. Based on these considera-
tions, CTC cannot at this stage be recommended as the primary
test for population CRC screening or in individuals with a positive
first-degree family history. However, it may be suggested as a
CRC screening test on an individual basis, providing the screenees
are adequately informed about test characteristics, benefits, and
risks.
CTC within a screening program, following positive
fecal testing with incomplete/unfeasible colonoscopy
ESGE/ESGAR strongly recommend CT colonography (CTC) in the case
of a positive fecal occult blood or fecal immunochemical test with in-
complete or unfeasible colonoscopy, within organized population
screening programs (strong recommendation, low quality evidence).
Repeated annual or biennial screening for colorectal cancer (CRC)
by guaiac-based fecal occult blood testing (FOBT) reduces dis-
ease-specific mortality by approximately 15%–18% [102]. Re-
sults of similar repeated screening by means of fecal immuno-
chemical testing (FIT) are awaited. It is assumed that the impact
on CRC-related mortality will be considerably higher than with
FOBT, because of the higher uptake of FIT testing, and the higher
sensitivity for advanced colorectal lesions [103]. This is con-
firmed by modelling studies [104]. This benefit is contingent on
confirmation and treatment of underlying cancer or adenoma
after a positive result. Colonoscopy combines sensitive diagnosis
with therapy by endoscopic resection and is therefore regarded
as the preferred test.
Since most screenees testing FOBT/FIT-positive will not have ad-
vanced neoplasia, CTC has been investigated as a possible triage
test to select patients with lesions only of greater size for colonos-
copy or surgery. The sensitivity of CTC for adenomas≥6mm was
above 85% in six studies [15,25,105–108] and was over 90% for
adenomas ≥10mm, a finding confirmed by a meta-analysis pub-
lished after our literature search [25]. A modelling study conclu-
ded that the use of CTC as an intermediate after positive FOBT/FIT
can only be cost-effective if the costs of CTC were ≤43% of the
costs of colonoscopy [109]. Furthermore, despite sensitivity ex-
ceeding 85%, lesion prevalence is so high that NPV is less than
might be expected, ranging from 85% to 95% in the studies in-
cluded. These factors mean that CTC should not be offered routi-
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nely to those testing FOBT/FIT-positive, and colonoscopy is pre-
ferable.
Since CTC does have good diagnostic performance, it may be con-
sidered for those unwilling to undergo colonoscopy or in whom
colonoscopy is unfeasible or incomplete, although screenees
should be informed that sensitivity (particularly for smaller ade-
nomas) is slightly inferior to that of colonoscopy. There is some
evidence that offering CTC to those who decline colonoscopy in-
creases uptake [110]. CTC is safe, and therefore may be preferable
in thosewith contraindications to colonoscopy or judged particu-
larly high risk, although observational data suggest absolute de-
tection rates may be lower than in healthy screenees who are fit
for colonoscopy [111]. Reasons for differences in detection rates
are unknown and only speculative at this stage. If the difference
is confirmed, and if it is due to suboptimal CTC practice (CTC
technique and/or image interpretation), procedures for guaran-
teeing high quality of CTC exams within organized population
screening programs will be necessary.
CT colonography and surveillance
!
Following curative-intent resection of colorectal cancer
ESGE/ESGAR suggest CT colonography (CTC) with intravenous con-
trast medium injection for surveillance after curative-intent resec-
tion of colorectal cancer only in patients in whom colonoscopy is un-
feasible (weak recommendation, low quality evidence).
Patients with resected colorectal cancer are at a 30% risk of recur-
rence [112,113] which can be either colonic or extracolonic. Lo-
cal recurrence is less common for colonic than rectal cancers
[112,114,115]. Recurrence can occur either at the site of anasto-
mosis or near the site of the primary resection. In contrast, meta-
chronous lesions are colorectal adenomas and cancers that devel-
op subsequently to the index cancer and do not originate from it.
Extracolonic recurrent disease comprises distant metastases in
the liver, lung, peritoneum, etc. CTC for postoperative surveil-
lance following potentially curative resection of colorectal carci-
noma has the potential to combine both colonic and extracolonic
examination, and is therefore an alternative to combined optical
colonoscopy and contrast-enhanced abdominal CT [116].
By means of a literature review, we identified eight cohort stud-
ies investigating contrast-enhanced CTC as a surveillance tool
after resection of colorectal cancer [116–123]. All of these stud-
ies demonstrated a high technical feasibility.
Local recurrence and metachronous colorectal cancer
In these studies, all local recurrent (n=65) and metachronous (n
=9) colonic cancers, were detected [116–123]. The largest study
included 548 patients who had subsequent colonoscopy and
pathologic confirmation of colonic lesions [116]. CTC sensitivity
for anastomotic andmetachronous recurrencewas 100%. Per-pa-
tient and per-lesion sensitivities for advanced neoplasia were
81.8% and 80.8%, respectively, and for all adenomatous lesions
they were 80.0% and 78.5%, respectively [116]. NPVs for adeno-
carcinoma, advanced neoplasia, and all adenomatous lesions
were 100%, 99.1%, and 97.0%, respectively. CTC enabled detec-
tion of clinically unsuspected metastatic disease in 11 patients,
none of them having a cancerous lesion in the colon [116].
CTC surveillance detection of adenoma/polyp
In a study on 548 consecutive patients, without clinical or labora-
tory evidence of recurrence following curative-intent CRC, who
underwent contrast-enhanced CTC and subsequent colonoscopy
and pathologic confirmation of colonic lesions, CTC sensitivity for
all adenomas of 80.0% (per-patient) and 78.5% (per-lesion) were
reported [116]. Unfortunately, accuracy data for these lesions
cannot be extracted from the other studies, because of the low
number of patients with polypoid lesions, inconsistent or insuffi-
cient reporting on the detection/presence of polyps/adenomas,
and/or lack of histological polyp data that impeded any stratifica-
tion and comparison of results [117–123].
CTC following polypectomy
ESGE/ESGAR suggest CT colonography (CTC) in patients with high
risk polyps in surveillance after polypectomy only when colonosco-
py is unfeasible (weak recommendation, low quality evidence).
The recent ESGE Guideline recommends endoscopic surveillance
only for patients with high risk adenomatous lesions (adenomas
with villous histology or high grade dysplasia or ≥10mm in size,
or ≥3 adenomas) or serrated lesions (≥10mm in size, or any de-
gree of cytological dysplasia) [124]. Colonoscopy is considered to
be the method of choice for post-polypectomy surveillance,
whose primary aim is to diagnose and remove polyps either mis-
sed at initial examination or newly developed during the time in-
terval between the index and follow-up examination. However,
compliancewith colonoscopic surveillance is relatively low, rang-
ing from 52% to 85%, with the highest levels obtained in research
settings [125–128]. Despite weak evidence supporting CTC for
surveillance [15], in patients who are unwilling or unable to un-
dergo colonoscopy, CTC is the best alternative because of its high
sensitivity and NPV, outperforming barium enema [11,22,29].
Safety of CT colonography
!
ESGE/ESGAR state that CT colonography (CTC) is contraindicated in
patients with active colonic inflammation and in those who have
recently undergone colorectal surgery (strong recommendation,
low quality evidence).
Despite being generally regarded as safer than colonoscopy [129],
CTC has been shown to be associated with potentially serious ad-
verse events, in particular perforation of the large bowel [130,
131]. Acute abdominal conditions, for example diverticulitis or
active inflammatory bowel disease (IBD), are absolute contrain-
dications to CTC, because of the relatively high risk of complica-
tion [132], and CTC should be avoided [130]. Unfortunately, there
are few studies supporting these strong recommendations. In a
recent meta-analysis [86] including more than 100 000 individ-
uals, 28 colonic perforations were reported. Moreover, eight
case reports–not included in the meta-analysis–detail CTC per-
foration [133–140]. These reports allow identification of some
risk factors for perforation. Among the 36 patients with perfora-
tion, four (11%) were affected by inflammatory bowel diseases,
four had a known inguinal hernia, and in one case the perforation
occurred after erroneous inflation of a rectal stump. Moreover,
mural frailty during active inflammation or in the postoperative
setting suggests that any procedure involving colonic distension
entails a risk.
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Colonoscopy following CT colonography
!
ESGE/ESGAR recommend referral for endoscopic polypectomy in pa-
tients with at least one polyp ≥6mm in diameter detected at CT co-
lonography (CTC). CTC surveillance may be clinically considered if pa-
tients do not undergo polypectomy (strong recommendation, mod-
erate quality evidence).
Polyp size and risk of advanced neoplasia
Diminutive polyps (≤5mm)
Most colorectal lesions encountered at endoscopy are polyps
≤5mm (i.e. diminutive) [141]. However, only a small proportion
of these lesions meet histological criteria for advanced neoplasia.
In detail, a recent systematic review of 28 947 polyps found the
frequency of advanced neoplasia to be 1.4% (408/28 947), while
the risk of invasive cancer was 0.03% (10/31 263) [142]. Little in-
formation is available regarding the natural history of untreated
≤5-mm polyps. In two prospective Northern European endo-
scopic studies, Hoff et al. [143] and Hofstad et al. [144] followed
up 194 diminutive and 253 ≤9mm polyps for 2 and 3 years,
respectively. No diminutive polyp reached >5mm in size and
only 0.5% of polyps ≤10mm exceeded the 10-mm threshold after
1 year; no cases of severe dysplasia or carcinoma were reported
[143,144]. Similar findings were reported by a Japanese study,
in which only 2.9% of 408 subcentimetric lesions followed up for
43.1 months reached ≥10mm size, without any invasive cancer
occurring [145].
Small polyps (6–9mm)
Overall, polyps of 6–9mm (i.e. small polyps) represent about
15% of all the polyps detected during primary screening colo-
noscopy [141]. In a recent systematic review of 8605 polyps,
the frequency of advanced neoplasia was 7.9%, while the pro-
portion with invasive cancer was 0.5% (10/8456] [142]. A retro-
spective analysis of 5124 individuals undergoing screening CTC
confirmed a very low risk of advanced neoplasia and invasive
cancer in 464 patients with polyps 6–9mm in size as the largest
lesion, corresponding to a 3.9% and 0% risk, respectively [146].
Recently, the natural history of 6–9-mm polyps detected at CTC
was addressed by a longitudinal study. Specifically, 243 adults
with 306 small polyps detected by CTC underwent a second CTC
after a 2–3-year follow-up [147]. Overall, 22% polyps had pro-
gressed, with 6% exceeding 10mm. The odds ratio was 16 for ad-
vanced adenoma among polyps that had shown growth during
surveillance compared with advanced adenoma among 6–9-
mm polyps detected and removed at initial CTC and colonoscopy
in a reference cohort. An absolute polyp volume of more than 180
mm³ at surveillance CTC was shown to predict advanced neopla-
sia (including one cancer) with a sensitivity of 92% (22 of 24
polyps), specificity of 94% (266 of 282 polyps), PPV of 58% (22 of
38 polyps), and NPV of 99% (266 of 268 polyps).
Recently, factors that may predict advanced neoplasia within a
subcentimeter polyp have been investigated. Kolligs et al. [148]
applied a logistic regression model to a large retrospectively ob-
tained cohort of 1077956 colonoscopies, in which 106270 small
and 198 954 diminutive lesions were removed. The risk of ad-
vanced neoplasia within subcentimetric lesions was associated
with increasing age, male sex, polyp morphology, polypmultipli-
city, and occult or overt blood in the stools.
Large polyps (≥10mm) and masses
Overall, ≥10-mm polyps (i. e. large polyps) represent about 10%
of all polyps detected during primary screening colonoscopy
[141]. In a previous systematic review, 73.5% (1363/1855) of
these polyps appeared to be advanced adenomas, the remainder
being nonadenomatous [141]. The prevalence of invasive cancer
has been recently addressed in large colonoscopic and CTC
screening series, with reported ranges between 2% and 7% [146,
148,149].
Same-day polypectomy
ESGE/ESGAR suggest same-day polypectomy as a possible option
after CT colonography (CTC) performed with full bowel preparation.
The implementation of this policy should take into account technical
and logistical factors, including patient consent (weak recommenda-
tion, low quality evidence).
Type of laxative used for CTC
Bowel preparation for CTC usually includes a low residue diet and
clear liquids for 24 hours or more, and a laxative preparation that
may be either a “wet prep” (e.g. polyethylene glycol [PEG]) or
“dry prep” (e.g. phosphosoda, magnesium citrate, etc). In the
studies identified in the literature search for CTC and same-day
colonoscopy, a range of different preparations was used, with ap-
proximately half using PEG, and the remaining using phosphoso-
da or a similar laxative. The rationale for laxative choicewas rare-
ly stated, although some studies documented that choice was
based on that routinely used for colonoscopy by the host institu-
tion. Furthermore, although data were sometimes presented on
quality of CTC preparation, few studies formally graded bowel
cleansing during same-day colonoscopy.
One large study of same-day CTC and colonoscopy in 734 patients
[105], investigated the quality of CTC imaging according to the CT
Colonography Reporting and Data System (C-RADS) and graded
the quality of bowel preparation at colonoscopy. Patients were
prepared before CTC, with clear liquid during the preceding 24
hours, 30ml sodium phosphate and 20mg bisacodyl as laxatives,
and oral barium and iodine agents for tagging. Only 3.1% of the
procedures were classified as inadequate for CTC interpretation;
in 20 of 23 cases this was due to insufficient insufflation. At colo-
noscopy, colonic preparation was classified by the endoscopist as
excellent or good in 63% of patients, fair in 28%, poor in 8.5%, and
inadequate in 0.5%.
A minority of studies commented regarding the quality of prepa-
ration during colonoscopy, but provided little detailed informa-
tion.
The fact that the literature is so sparse regarding quality of prep-
aration during same-day colonoscopy does suggest that it is not a
major issue. However it cannot be determined from the available
literature which bowel preparation is preferred for same-day co-
lonoscopy after CTC. Although the frequency and extent of reten-
tion of fecal material and fluids at CTC has been extensively stud-
ied, the effects of the various CTC preparation protocols on the
performance of same-day colonoscopy is less well known.
Laxative-free CTC
Reduced bowel preparations at CTC are gaining popularity but
may prevent same-day endoscopy (although minor fecal residue
may be suctioned during colonoscopy). Our literature search
found no information regarding the quality of same-day colonos-
copy after same-day laxative-free CTC. However several studies
have reported using additional bowel cleansing subsequent to
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laxative-free CTC when same-day colonoscopy is required. For
example, in a study of 95 symptomatic patients undergoing re-
duced-laxative CTC, senna and 18g magnesium citrate were
used, with an additional 18g of magnesium citrate after CTC but
prior to colonoscopy [150]. Lefere et al. [151] compared standard
bowel preparation, reduced bowel preparation, and oral barium
for fecal tagging in 100 patients having CTC with same-day colo-
noscopy. In order to compensate for reduced bowel purgation,
which may prohibit colonoscopy, PEG was administered after
CTC, and colonoscopy performed 2–3 hours later.
Fecal tagging
Fecal tagging with oral barium or hyperosmolar/iso-osmolar io-
dine solutions or both is now considered mandatory for CTC [7].
Occasionally, concern has been raised that when barium is used,
it may interfere with the diagnostic quality of same-day colonos-
copy, potentially obscuring the endoscopic view by coating the
colonic mucosa. Others have suggested that retained barium and
iodine-based contrast agents are easily aspirated or flushed out
of the way during endoscopy, and therefore are of no concern.
Our literature search, including studies of same-day CTC and co-
lonoscopy with or without fecal tagging, found little specific in-
formation on this issue. Frequency of incomplete colonoscopy
was commonly cited, indicating causes such as tortuous bowel,
pain, or strictures, but problems specifically related to fecal tag-
ging were rarely mentioned.
Pickhardt et al. [18] analyzed 1233 asymptomatic patients under-
going CTC (with fecal and fluid tagging) and same-day colonosco-
py with segmental unblinding. The quality of bowel preparation
was not formally reported but only six of 1253 patients were ex-
cluded initially because of inadequate colonic preparation. Sub-
optimal colonoscopy quality was dismissed as a reason for mis-
sed adenomas since the colonoscopy completion rate was high
at 99.4%.
A similar tagging regimen was used in another large study, men-
tioned above, of same-day CTC and colonoscopy in a population
at average or high risk of colorectal cancer [105]. The quality of
CTC imaging was assessed by the radiologist according to the C-
RADS system and the quality of bowel preparation at colonosco-
py was graded by the endoscopist on a 5-point scale, from excel-
lent to inadequate. At colonoscopy, 63% of caseswere classified as
excellent or good, 28% as fair, 8.5% as poor and 0.5% as inade-
quate. At CTC, 23 (3.1% of the cases) cases were classified as C0,
which includes preparation or insufflation that is inadequate for
satisfactory interpretation; as noted above, 20 of the 23 cases
were due to inadequate insufflation. These 23 cases were classi-
fied at colonoscopy as having excellent or good preparation in
65%, fair in 30%, and poor or inadequate in 5%. There was no
mention that tagging agents were a complicating factor at colo-
noscopy.
It can therefore be inferred indirectly from the relatively large
number of comparative same-day CTC and conventional colonos-
copy studies aimed at diagnostic accuracy, that fecal tagging like-
ly does not negatively affect colonoscopy results.
Logistics of same-day colonoscopy
To provide same-day endoscopy after CTC, the indications and lo-
gistics concerning patient selection, timing, patient transporta-
tion, availability of endoscopists and endoscopy suites etc. must
be pre-planned jointly by radiology and endoscopy units. This
modality also requires that CTC findings are reviewed by a radiol-
ogist immediately in order to identify patients in whom same-
day colonoscopy is needed, and in order to identify the rare but
well-recognised perforations that occur during CTC.
When a lesion detected at CT colonography (CTC) is not confirmed
by a high quality colonoscopy, ESGE/ESGAR recommend careful re-
view of the CTC findings. In cases when post-colonoscopy radiolog-
ical confidence for the presence of a ≥10-mm lesion remains high,
early repetition of colonoscopy should be considered (weak recom-
mendation, low quality evidence).
It is possible that colorectal lesions reported at CTC may not be
detected at colonoscopy, either because they are CTC false posi-
tives or colonoscopic false negatives. Clinical consequences in-
clude progression of colonoscopic false-negative polyps towards
invasive CRC or anxiety due to CTC false-positive findings. In a re-
cent prospective multicenter study of symptomatic patients, the
PPV of CTC for large polyps was about 60%, indicating that colo-
noscopic inability to confirm CTC findings occurs frequently [11].
The sensitivity of colonoscopy for ≥10-mmpolyps is higher [152],
and may be presumed to be substantially increased when–as oc-
curs in daily practice– the endoscopist is searching specifically
for a CTC finding. Therefore, the possibility of missing large le-
sions at such colonoscopies may be considered too low to war-
rant a further endoscopic examination. However, it is well known
that colonoscopy is not 100% sensitive even for large lesions that
are present at CTC, a phenomenon that has been explained by the
existence of colonoscopic “blind spots” [153]. Most post-colono-
scopic interval cancers are related to missed rather than new le-
sions. In contrast to 6–9-mm polyps, the risk of established can-
cer in larger lesions is relevant [149]. Thus if, after negative colo-
noscopy findings, confidence in the CTC diagnosis remains high,
an early repetition of colonoscopy should be considered, espe-
cially if the abnormality appears to be related to flexures or to
be on the proximal side of colonic haustra.
ESGE guidelines represent a consensus of best practice based on
the available evidence at the time of preparation. They may not
apply in all situations and should be interpreted in the light of
specific clinical situations and resource availability. Further con-
trolled clinical studies may be needed to clarify aspects of these
statements, and revision may be necessary as new data appear.
Clinical consideration may justify a course of action at variance
to these recommendations. ESGE guidelines are intended to be
an educational device to provide information that may assist en-
doscopists in providing care to patients. They are not rules and
should not be construed as establishing a legal standard of care
or as encouraging, advocating, requiring, or discouraging any
particular treatment.
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